Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease

被引：0

作者：

Dzamko, Nicolas ^{[1
]}

机构：

[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Camperdown, NSW, Australia

来源：

BIOCHEMICAL JOURNAL | 2025年 / 482卷 / 11期

关键词：

MITOCHONDRIAL-DNA DAMAGE; RAB10; PHOSPHORYLATION; ALPHA-SYNUCLEIN; LRRK2; MUTATIONS; BIS(MONOACYLGLYCEROL)PHOSPHATE; EXOSOMES; MONITOR; CELLS; GENE;

D O I：

10.1042/bcj20253099

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has emerged as a promising therapeutic target for the treatment of neurodegenerative Parkinson's disease (PD). Data from a multitude of pre-clinical models are supportive of a potential role for LRRK2 therapies to ameliorate cellular dysfunctions found in PD, and small molecules to inhibit LRRK2 kinase activity, as well as antisense oligonucleotides to target the protein itself, are in clinical trials. Despite this, exactly how LRRK2 contributes to PD pathogenesis remains to be determined, and definitive biomarkers to track LRRK2 function are still required. Such biomarkers can be useful for monitoring the pharmacodynamic response of LRRK2 therapeutics and/or understanding the relationship between LRRK2 and the clinical progression of PD. Moreover, biomarkers that can identify increased LRRK2 levels or activity beyond just carriers of pathogenic LRRK2 mutations will be important for expanding LRRK2 therapeutics to other PD populations. This review summarizes recent findings regarding biomarkers of LRRK2.

引用

页码：711 / 722

页数：12

共 98 条

[61] Targeted Ablation of Primary Cilia in Differentiated Dopaminergic Neurons Reduces Striatal Dopamine and Responsiveness to Metabolic Stress [J].

Mustafa, Rasem ;

Rawas, Chahinaz ;

Mannal, Nadja ;

Kreiner, Grzegorz ;

Spittau, Bjoern ;

Kaminska, Katarzyna ;

Yilmaz, Ruestem ;

Poetschke, Christina ;

Kirsch, Joachim ;

Liss, Birgit ;

Tucker, Kerry L. ;

Parlato, Rosanna .

ANTIOXIDANTS, 2021, 10 (08)

[62] A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells [J].

Naaldijk, Yahaira ;

Fernandez, Belen ;

Fasiczka, Rachel ;

Fdez, Elena ;

Leghay, Coline ;

Croitoru, Ioana ;

Kwok, John B. ;

Boulesnane, Yanisse ;

Vizeneux, Amelie ;

Mutez, Eugenie ;

Calvez, Camille ;

Destee, Alain ;

Taymans, Jean-Marc ;

Aragon, Ana Vinagre ;

Yarza, Alberto Bergareche ;

Padmanabhan, Shalini ;

Delgado, Mario ;

Alcalay, Roy N. ;

Chatterton, Zac ;

Dzamko, Nicolas ;

Halliday, Glenda ;

Ruiz-Martinez, Javier ;

Chartier-Harlin, Marie-Christine ;

Hilfiker, Sabine .

NPJ PARKINSONS DISEASE, 2024, 10 (01)

[63] 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization [J].

Nichols, R. Jeremy ;

Dzamko, Nicolas ;

Morrice, Nicholas A. ;

Campbell, David G. ;

Deak, Maria ;

Ordureau, Alban ;

Macartney, Thomas ;

Tong, Youren ;

Shen, Jie ;

Prescott, Alan R. ;

Alessi, Dario R. .

BIOCHEMICAL JOURNAL, 2010, 430 :393-404

[64] Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease [J].

Nichols, R. Jeremy ;

Dzamko, Nicolas ;

Hutti, Jessica E. ;

Cantley, Lewis C. ;

Deak, Maria ;

Moran, Jennifer ;

Bamborough, Paul ;

Reith, Alastair D. ;

Alessi, Dario R. .

BIOCHEMICAL JOURNAL, 2009, 424 :47-60

[65] Centrioles, Centrosomes, and Cilia in Health and Disease [J].

Nigg, Erich A. ;

Raff, Jordan W. .

CELL, 2009, 139 (04) :663-678

[66] Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites [J].

Nirujogi, Raja S. ;

Tonelli, Francesca ;

Taylor, Matthew ;

Lis, Pawel ;

Zimprich, Alexander ;

Sammler, Esther ;

Alessi, Dario R. .

BIOCHEMICAL JOURNAL, 2021, 478 (02) :299-326

[67] An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson?s Disease and G2019S LRRK2 Cohorts [J].

Padmanabhan, Shalini ;

Lanz, Thomas A. ;

Gorman, Donal ;

Wolfe, Michele ;

Joyce, Alison ;

Cabrera, Carlos ;

Lawrence-Henderson, Rosemary ;

Levers, Najah ;

Joshi, Neal ;

Ma, Thong C. ;

Liong, Christopher ;

Narayan, Sushma ;

Alcalay, Roy N. ;

Hutten, Samantha J. ;

Baptista, Marco A. S. ;

Merchant, Kalpana .

JOURNAL OF PARKINSONS DISEASE, 2020, 10 (02) :623-629

[68] Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease [J].

Paisán-Ruíz, C ;

Jain, S ;

Evans, EW ;

Gilks, WP ;

Simón, J ;

van der Brug, M ;

de Munain, AL ;

Aparicio, S ;

Gil, AM ;

Khan, N ;

Johnson, J ;

Martinez, JR ;

Nicholl, D ;

Carrera, IM ;

Pena, AS ;

de Silva, R ;

Lees, A ;

Martí-Massó, JF ;

Pérez-Tur, J ;

Wood, NW ;

Singleton, AB .

NEURON, 2004, 44 (04) :595-600

[69] Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker [J].

Perera, G. ;

Ranola, M. ;

Rowe, D. B. ;

Halliday, G. M. ;

Dzamko, N. .

SCIENTIFIC REPORTS, 2016, 6

[70] A blood-based marker of mitochondrial DNA damage in Parkinson's disease [J].

Qi, Rui ;

Sammler, Esther ;

Gonzalez-Hunt, Claudia P. ;

Barraza, Ivana ;

Pena, Nicholas ;

Rouanet, Jeremy P. ;

Naaldijk, Yahaira ;

Goodson, Steven ;

Fuzzati, Marie ;

Blandini, Fabio ;

Erickson, Kirk I. ;

Weinstein, Andrea M. ;

Lutz, Michael W. ;

Kwok, John B. ;

Halliday, Glenda M. ;

Dzamko, Nicolas ;

Padmanabhan, Shalini ;

Alcalay, Roy N. ;

Waters, Cheryl ;

Hogarth, Penelope ;

Simuni, Tanya ;

Smith, Danielle ;

Marras, Connie ;

Tonelli, Francesca ;

Alessi, Dario R. ;

West, Andrew B. ;

Shiva, Sruti ;

Hilfiker, Sabine ;

Sanders, Laurie H. .

SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (711)

← 1 2 3 4 5 6 7 8 9 10 →